Aca­cia Phar­ma's twice spurned drug fi­nal­ly makes the FDA cut

Third time’s the charm for Aca­cia Phar­ma.

The Cam­bridge, UK-based com­pa­ny on Thurs­day fi­nal­ly se­cured FDA ap­proval for its treat­ment for pa­tients with post­op­er­a­tive nau­sea & vom­it­ing (PONV), who are symp­to­matic de­spite hav­ing re­ceived pro­phy­lac­tic treat­ment.

The drug, an in­tra­venous for­mu­la­tion of the se­lec­tive dopamine D2 and D3 an­tag­o­nist amisul­pride, was shown to help pa­tients in four pos­i­tive piv­otal clin­i­cal tri­als by 2017. But man­u­fac­tur­ing trou­bles re­peat­ed­ly hob­bled the com­pa­ny’s quest to get the ther­a­py — brand­ed Barhem­sys — on to the US mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER